Guselkumab
Interleukin-23 Antagonist — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Also known as: CNTO 1959, tremfya
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Guselkumab is a drug in the Interleukin-23 Antagonist class catalogued in DrugCentral. It was first approved by the FDA in 2017. Its mechanism of action is classified as Interleukin-23 Antagonists. DrugCentral lists 1 molecular target, including IL12B|IL23A. Recorded indications include Palmoplantar pustulosis and Plaque psoriasis.
- Drug class: Interleukin-23 Antagonist.
- Mechanism of action: Interleukin-23 Antagonists.
- Molecular targets: IL12B|IL23A (1 listed in DrugCentral).
- Indications: Palmoplantar pustulosis and Plaque psoriasis.
- ATC code: L04AC16 (Interleukin inhibitors).
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (2)
- Palmoplantar pustulosis
- Plaque psoriasis
Mechanism & targets
| Mechanism of action (MoA) | Interleukin-23 Antagonists |
|---|---|
| Established pharmacologic class | Interleukin-23 Antagonist |
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Interleukin-23 | IL12B|IL23A | other | — |
Regulatory approvals (3)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2018-03-23 | PMDA | — | Janssen Pharmaceutical KK | |
| 2017-11-10 | EMA | — | Janssen-Cilag International N.V. | |
| 2017-07-13 | FDA | — | JANSSEN BIOTECH |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
L04AC16 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Interleukin inhibitors |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Product dose omission issue | 16150.6 |
| Accidental exposure to product | 4685.9 |
| Needle issue | 4259.1 |
| Device deployment issue | 2941.7 |
| Device issue | 2705.1 |
| Device malfunction | 2455.8 |
| Product leakage | 2084.9 |
| Device defective | 2054.4 |
| Drug delivery system malfunction | 1911.3 |
| Device leakage | 1665.0 |
| Product storage error | 1156.4 |
| Syringe issue | 732.5 |
Chemical structure
| Molecular formula | — |
|---|---|
| Molecular weight | — |
| CAS number | 1350289-85-8 |
| InChIKey | — |
| PubChem CID | — |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Guselkumab used for?
DrugCentral lists the following indications for Guselkumab: Palmoplantar pustulosis and Plaque psoriasis.
How does Guselkumab work?
Guselkumab is classified as Interleukin-23 Antagonists; its molecular targets in DrugCentral include IL12B|IL23A.
When was Guselkumab first approved?
Guselkumab was first approved by the FDA in 2017.
What drug class does Guselkumab belong to?
Guselkumab is in the Interleukin-23 Antagonist class.
Browse: all drugs starting with G · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5246 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL2364648 — compound record and bioactivity
- DrugBank DB11834 — drug record
- FDA UNII 089658A12D — substance identity
- DailyMed: FDA labels for Guselkumab — current prescribing information (label search)
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.